Bovijn et al. [18] found that sclerostin lowering increased the risk of MI, MACE, type 2 diabetes mellitus (T2DM) and hypertension, increased triglyceride levels and reduced HDL (Table 1). This evidence concerns the gene SOST and type 2 diabetes mellitus.